Global Information
회사소개 | 문의 | 비교리스트

세계의 디지털 치료 시장

Digital Therapeutics

리서치사 Global Industry Analysts, Inc.
발행일 2022년 01월 상품 코드 903083
페이지 정보 영문 202 Pages
가격
US $ 4,950 ₩ 5,962,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 14,850 ₩ 17,886,000 PDF (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 디지털 치료 시장 Digital Therapeutics
발행일 : 2022년 01월 페이지 정보 : 영문 202 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 디지털 치료(Digital Therapeutics) 시장을 조사했으며, 시장 개요, 부문·지역별 시장 규모 추정과 예측, 시장 동향 및 성장 촉진요인 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
    • 경쟁사의 시장 점유율
    • 경쟁사의 시장 점유율 : 시나리오
  • 주목 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 지역 시장 분석
  • 미국
    • 개요
    • 기업의 시장 점유율
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 기타 유럽 국가
  • 아시아태평양
  • 기타 지역

제4장 경쟁 상황

  • 2MORROW, INC.
  • CANARY HEALTH
  • GINGER.IO
  • LIVONGO HEALTH
  • MANGO HEALTH
  • NOOM INC.
  • OMADA HEALTH, INC.
  • PROPELLER HEALTH
  • PROTEUS DIGITAL HEALTH, INC.
  • WELLDOC

제5장 조사 자료

KSM 19.09.17

Abstract:

Global Digital Therapeutics Market to Reach US$12.1 Billion by the Year 2026

Digital therapeutics (DTx), an emerging trend in the rapidly growing mobile health (mHealth) space comprises software programs that blend medical intervention with digital platforms for treatment of medical disorder or conditions. Digital therapeutics enables improved health monitoring, prevention and management leading to improved health outcomes and reduced healthcare expenditure. With rising penetration of smartphones and internet usage, digital therapeutics can offer basic medical guidance, work in combination with drug regimens, use cognitive stimulation to induce behavioural changes, connect with wearables and medical equipment through the use of mobile apps. Rising incidences of chronic diseases, growing geriatric population, technological advancements, benefits of digital therapeutics, and pressing need to curb rising healthcare costs are key growth drivers spurring significant growth in the global market. Strong adoption of digital platforms like smartphones, apps, electronic wearables, mobile internet; growing focus on value based care; and rising venture capital investments in digital health based business models spur growth in the market. The momentum is likely to accelerate further with advent of next-generation technologies such as IoT and Artificial Intelligence (AI), as these `high-tech` modalities hold immense potential to augment roll out of DTx interventions as a complementary product or as a complete replacement to traditional therapeutics.

Amid the COVID-19 crisis, the global market for Digital Therapeutics estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$12.1 Billion by 2026, growing at a CAGR of 27.7% over the analysis period. B2B, one of the segments analyzed in the report, is projected to grow at a 28.8% CAGR to reach US$13.3 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the B2C segment is readjusted to a revised 19.2% CAGR for the next 7-year period. This segment currently accounts for a 12.9% share of the global Digital Therapeutics market.

The U.S. Market is Estimated at $1.4 Billion in 2021, While China is Forecast to Reach $909.2 Million by 2026

The Digital Therapeutics market in the U.S. is estimated at US$1.4 Billion in the year 2021. The country currently accounts for a 41.8% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$909.2 Million in the year 2026 trailing a CAGR of 28.9% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 23.8% and 22.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 27% CAGR while Rest of European market (as defined in the study) will reach US$1.2 Billion by the end of the analysis period. The United States and Europe represent key markets, led supported by well-developed digital infrastructure that provides the foundation for DTx. In Asia-Pacific region, growth is driven by rising prevalence of chronic illnesses and growing geriatric population.

Select Competitors (Total 108 Featured) -

  • Canary Health, Inc.
  • Dthera Sciences
  • Fitbit Health Solutions
  • Livongo Health, Inc.
  • Medtronic, Plc
  • Omada Health, Inc.
  • Propeller Health
  • Pear Therapeutics, Inc.
  • Proteus Digital Health, Inc.
  • WellDoc, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • 2020: A Year of Disruption & Transformation
    • As the Race between the Virus & Vaccines Intensifies, Review of the World Economy in 2021
    • EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    • COVID-19 Pandemic Expedites Implementation of Digital Therapeutics
    • Prominent Drivers Enabling Digital Therapeutics Market to Leapfrog
    • Digital Therapeutics: An Introduction
    • EXHIBIT 2: Digital Therapeutics Market by Disease Condition: 2021E
    • Outlook
    • Strategies to Push Uptake of Digital Therapeutics
    • Leading Markets
    • Factors Impeding Growth
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Digital Therapeutics Continue to Attract Venture Capital Investments
    • EXHIBIT 3: Digital Health Funding by Segment (in US$ Million): 2020
    • EXHIBIT 4: Top Funded Clinical Indications: 2020
    • EXHIBIT 5: Top Funded Clinical Indications: Q1-Q3 2021
    • EXHIBIT 6: Digital Therapeutics Funding in US$ Million: 2018-2021 9 Months
    • EXHIBIT 7: Digital Therapeutics Deal Count: 2018-2021 9 Months
    • Startups Flock the Digital Therapeutics Market
    • Select Digital Therapeutics Startups
    • EXHIBIT 8: Quarterly Investments by Digital Therapeutics Startups in US$ Million: Q1 2020 to Q3 2021
    • EXHIBIT 9: Top 10 Equity Deals in Q3'21
    • Pipeline Products Drive Growth Prospects
    • Select FDA Approved DTx
    • A Snapshot of Select DTx Pipeline Products
    • Artificial Intelligence to Play a Significant Role in Improving Clinical Outcomes
    • EXHIBIT 10: Global Healthcare Artificial Intelligence Market by Application: 2021
    • Why Healthcare & Pharmaceuticals are joining the Digital Therapeutics Bandwagon?
    • Pharma Majors Foray into Uncharted Territory
    • Pharmaceutical Companies Team Up with Payers to Seek Reimbursement
    • Growing Need to Break the Stigma Associated with Mental Health Augurs well for Digital Therapeutics
    • Select Mental Health Stats Worldwide
    • Potential Areas for Digital Therapeutics
    • EXHIBIT 11: Global Number of People Suffering from Mental Disorders (In Million)
    • Pandemic Pulls up Lever for Digital Mental Healthcare
    • EXHIBIT 12: Anxiety and Depression on Rise Amid the Pandemic: Percentage of US Adults Displaying Symptoms of Anxiety and Depressive Disorder (Jan-June 2019, May 2020, and December 2020)
    • High Prevalence of Chronic Diseases and Growing Focus on Preventative Healthcare Widens Growth Opportunities
    • Role of Digital Therapeutics in Type 2 Diabetes Reversal
    • EXHIBIT 13: World Diabetes and Population Statistics (2019, 2030 & 2045)
    • EXHIBIT 14: World Diabetes Prevalence: 2000-2019, 2030 and 2045
    • Growing Overweight and Obese Population Benefit Market Prospects
    • EXHIBIT 15: Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025
    • EXHIBIT 16: COVID-19 Pandemic Adds to the Healthcare Burden of Nations Worldwide: Obesity-Related Health Spending as % of Total Health Expenditure for the Period 2020-2050
    • Managing Heart Failure through Digital Interventions
    • EXHIBIT 17: Global Annual Medical Cost of CVD in US$ Billion (2010-2030)
    • Neurological Conditions
    • EXHIBIT 18: Chronic Disease Management in Developed Countries (2019): Percentage Distribution of Patient Population by Chronic Disease Type in the US, Germany, and UK
    • How Digital Therapeutics is Changing Oncology Care Landscape?
    • EXHIBIT 19: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Data Generation for Drug Development
    • Proliferation of Smart Devices Bodes Well for Market Growth
    • EXHIBIT 20: Smartphone Adoption as Share of Total Population: 2016-2021
    • Mobile Healthcare Gains Momentum amid the Pandemic
    • EXHIBIT 21: Global Smartphone Shipments in Million Units: 2010-2021
    • Delivery through Wearable Devices Holds Strong Potential
    • EXHIBIT 22: Global Wearable Device Shipments in Million Units for the Years 2017, 2019, 2021, 2023, and 2025
    • Growing Focus on Reducing Healthcare Costs Bolsters Market Growth
    • EXHIBIT 23: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Digital Therapeutics Evolves as a Viable Solution for Medication Adherence
    • Aging Population and their Vulnerability to Various Health Conditions: A Vital Growth Driver
    • EXHIBIT 24: Global Population for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Digital Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Digital Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027
    • TABLE 3: World Current & Future Analysis for B2B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for B2B by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 5: World Current & Future Analysis for B2C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for B2C by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 7: World Current & Future Analysis for Treatment / Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World 7-Year Perspective for Treatment / Care by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 9: World Current & Future Analysis for Preventive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 10: World 7-Year Perspective for Preventive by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 11: USA Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 12: USA 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 13: USA Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 14: USA 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • CANADA
    • TABLE 15: Canada Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 16: Canada 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 17: Canada Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 18: Canada 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • JAPAN
    • TABLE 19: Japan Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Japan 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 21: Japan Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 22: Japan 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • CHINA
    • TABLE 23: China Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 24: China 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 25: China Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: China 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • EUROPE
    • TABLE 27: Europe Current & Future Analysis for Digital Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 28: Europe 7-Year Perspective for Digital Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027
    • TABLE 29: Europe Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 30: Europe 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 31: Europe Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Europe 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • FRANCE
    • TABLE 33: France Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 34: France 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 35: France Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 36: France 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • GERMANY
    • TABLE 37: Germany Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Germany 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 39: Germany Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 40: Germany 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • ITALY
    • TABLE 41: Italy Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 42: Italy 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 43: Italy Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Italy 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • UNITED KINGDOM
    • TABLE 45: UK Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 46: UK 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 47: UK Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 48: UK 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • REST OF EUROPE
    • TABLE 49: Rest of Europe Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of Europe 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 51: Rest of Europe Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 52: Rest of Europe 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • ASIA-PACIFIC
    • TABLE 53: Asia-Pacific Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 54: Asia-Pacific 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 55: Asia-Pacific Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Asia-Pacific 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • REST OF WORLD
    • TABLE 57: Rest of World Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 58: Rest of World 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 59: Rest of World Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 60: Rest of World 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 108
Back to Top
전화 문의
F A Q